GLYCOMINE

Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. Even though the number of patients affected by any single disease may total several hundred or thousand, it is estimated the total number of people affected by all such diseases is more than 20 million in the U.S. alone... Glycomine is developing replacement therapies for rare genetic diseases with the goal of delivering meaningful improvements in quality of life for patients, caregivers, and families... Rare genetic diseases are often caused by genetic mutations that lead to protein dysfunction and disruption of biochemical pathways. Glycomine is developing replacement therapies, where delivering a substrate, enzyme, or protein has the potential to restore the missing function. GLM101 is Glycomine's first drug from its platform..

Also known as: Glycomine, Inc.

Primary location: San Carlos United States